Efficacy of Transcutaneous Electrical Nerve Stimulation in Management of Cancer Pain: a Meta Analysis

Alan D. Kaye, LSU Health Sciences Center - Shreveport
Kaitlyn E. Allen, LSU Health Sciences Center - New Orleans
Shivam S. Shah, LSU Health Sciences Center - Shreveport
Summer A. Smith, LSU Health Sciences Center - New Orleans
Taylor R. Plaisance, LSU Health Sciences Center - New Orleans
Amy E. Brouillette, LSU Health Sciences Center - New Orleans
Dani’elle J. Despanie, LSU Health Sciences Center - New Orleans
Tayler D. Payton, LSU Health Sciences Center - New Orleans
Ross Rieger, LSU Health Sciences Center - Shreveport
Naina Singh, LSU Health Sciences Center - Shreveport
Shahab Ahmadzadeh, LSU Health Sciences Center - Shreveport
Sonja Gennuso, LSU Health Sciences Center - Shreveport
Sahar Shekoohi, LSU Health Sciences Center - Shreveport

Abstract

Purpose of Review: The present investigation assesses efficacy of transcutaneous electrical nerve stimulation (TENS) on relief of cancer or chemotherapy-related pain. Patients with cancer experience a relatively high prevalence of pain that is reportedly undertreated. Therefore, this analysis is pertinent to determine if TENS is a useful complementary therapy considering its increase in accessibility and minimal side effect profile. Recent Findings: A systematic search for eligible studies from PubMed, Google Scholar, Cochrane, and Embase was performed. The present investigation elucidated any significant differences between change in numeric rating scale of average and maximum pain scores between a TENS and non-TENS group. A nonsignificant difference was reported between TENS and non-TENS, with a mean difference of − 0.393 (95% CI − 1.780, 0.993; P = 0.578). For change in maximum pain reported, a nonsignificant difference was also found, with a mean difference of 0.128 (95% CI − 1.158, 1.414; P = 0.845). Conclusion: Related to various limitations of this meta-analysis, no definitive conclusions could be concluded regarding efficacy of TENS in the treatment of cancer or chemotherapy-related pain. Additional randomized primary studies with standardized treatment protocols and pain measurements are needed for future meta-analysis and recommendations for clinical practice.